Background. Multidrug-resistant gram-negative bacterial (MDR-GNB) infections of the prostate are an increasing problem worldwide, particularly complicating transrectal ultrasound (TRUS)-guided prostate biopsy. Fluoroquinolonebased regimens, once the mainstay of many protocols, are increasingly ineffective. Fosfomycin has reasonable in vitro and urinary activity (minimum inhibitory concentration breakpoint ≤64 µg/mL) against MDR-GNB, but its prostatic penetration has been uncertain, so it has not been widely recommended for the prophylaxis or treatment of MDR-GNB prostatitis.
Urinary and prostatic infections due to multidrugresistant gram-negative Enterobacteriaceae (MDR-GNB) are an increasing clinical problem worldwide [1] [2] [3] . In particular, resistance to fluoroquinolones has been especially problematic given their central role in prophylaxis prior to transrectal ultrasound (TRUS)-guided prostatic biopsies [4] and the treatment of established prostatitis [5] . Fosfomycin can be a potentially useful agent for urinary tract sepsis due to MDR-GNB, as many such strains remain susceptible to this older agent [6, 7] . It is for this reason and the drug's ease of administration that it has been widely recommended and used in the treatment of uncomplicated urinary tract infection [8] . However, due to very limited data regarding the penetration of fosfomycin into the prostate [9, 10] , no guidelines have thus far recommended its use where prostatic infection is a possibility.
We prospectively assessed the penetration of fosfomycin into benign prostatic tissue in a large cohort of otherwise healthy men undergoing transurethral resection of the prostate (TURP) and compared these to the corresponding urine and serum concentrations, to assess the possible pharmacokinetic characteristics of this agent for pre-TRUS prophylaxis or treatment of prostatitis.
METHODS
We prospectively recruited otherwise healthy males who required TURP for benign prostatic hyperplasia from the Urology Department Outpatient clinic at Austin Health, an 800-bed acute tertiary care hospital in Melbourne, Australia, from December 2010 to June 2011. Patients with proven prostate cancer, severe renal impairment (defined as estimated glomerular filtration rate [eGFR] <40 mL/minute), treatment with any antimicrobials within 1 month, or a history of intolerance/ allergy to fosfomycin were excluded. The study was approved by the Austin Health Human Research Ethics Committee; all participants provided informed consent.
All participants received a single 3-g dose of oral fosfomycin tromethamine alone prior to fasting for their TURP surgery as presurgical prophylaxis, with the time of fosfomycin administration recorded by the patient. No other antibiotics were administered before surgery. At the commencement of the TURP procedure, a single blood sample was drawn. Urine was collected on insertion of a standard 24Fr monopolar transurethral resectoscope, and prostatic tissue samples were obtained from both the transition zone and the peripheral zone of the prostate, as these sites are known to have different degrees of vascularity [11] . The collection time of all samples was recorded. Prostate samples were dissected, weighed, and placed in specifically designated homogenizer tubes (QIAcube RB, Qiagen Australia), before storage at −70°C until subsequent analysis. Similarly, plasma and urine specimens were stored at −70°C until analysis.
Fosfomycin was measured by a liquid chromatographytandem mass spectrometry (LC-MS/MS) using an electrospray negative ion mode ionization method adapted from Li et al [12] . Thawed plasma and urine (200 µL) had internal standard solution (200 µg/mL 13 C 3 -fosfomycin in 0.1% ethylenediaminetetraacetic acid [EDTA]) added (10 µL), then the sample proteins were precipitated by the addition of methanol (800 µL) and vortex mixing. Similarly, each prostatic tissue sample was removed from storage and had internal standard solution (200 µg/mL 13 C 3 -fosfomycin in 0.1% EDTA) (10 µL), 0.1% EDTA (200 µL), and a 7-mm stainless steel ball (Qiagen Australia) added. The tissue was immediately homogenized (10 minutes at 50 Hz, TissueLyserII, Qiagen Australia) and the sample proteins were precipitated by the addition of methanol (800 µL) and vortex mixing.
After protein precipitation, all samples were centrifuged (5 minutes at 20 000g), and supernatant (2 µL injection volume) was analyzed using LC-MS/MS (Model 6460, Agilent Australia). Dynamic multiple reaction monitoring followed quantifier and qualifier transitions (m nominal, n ≥ 6 each at lower concentration levels) for each of the matrices was ±0.5% plasma at 5 µg/mL, ±3.2% in urine at 100 µg/mL, and ±14.6% at 1.0 µg/mL in tissue from different patients and a range of tissue sample sizes. Precision data (Coefficient of variation [%], n ≥ 5) for each matrix were 5.1% in plasma, 9.8% in urine, and 6.4% in tissue from different patients and a range of tissue sample sizes. Fosfomycin concentrations in urine, plasma, and prostatic tissues (and their timing) were compared for each patient to determine the ratio of intraprostatic drug penetration. Statistical differences in fosfomycin concentrations in the transition and peripheral zones were compared using a paired t test; P ≤ .05 was considered significant.
RESULTS
Twenty-six patients participated in the study; mean age, weight, and eGFR were 68 ± 9 years (range, 51-83 years), 86.2 ± 13 kg (range, 62-109 kg), and 67 ± 12 mL/minute/1.73 m 2 (range, 43-86 mL/minute/1.73 m 2 ), respectively. Sufficient prostatic tissue was available for analysis in all 26 participants for the transitional prostatic zone and 23 of 26 for the peripheral prostatic zone.
Results for urine, serum, and prostatic concentrations of fosfomycin, as well as the timing of specimen collection compared to dose administration, are summarized in Table 1 and Figure 1 . Mean plasma fosfomycin levels were 11.4 ± 7.6 µg/mL (range, 2.29-40.38 µg/mL; median, 10.84 µg/mL) at 565 ± 149 minutes after fosfomycin administration; mean urinary levels were 571 ± 418 µg/mL (range, 48-1522 µg/mL; median, 434.86 µg/mL) at 581 ± 150 minutes postdose.
Mean overall prostate fosfomycin levels were 6.5 ± 4.9 µg/g (range, 0.7-22.1 µg/g; median, 2.97 µg/g), with potentially therapeutic concentrations detectable up to 17 hours following the dose (see patient 15, Table 1 ). Overall, the mean prostate to plasma ratio was 0.67 ± 0.57. Mean concentrations within the transition and peripheral prostate regions varied significantly (transition, 8.3 ± 6.6 vs peripheral, 4.4 ± 4.1 µg/g; P = .001). Only 1 patient had a mean prostatic fosfomycin concentration of <1 µg/g, whereas the majority (18/26 [70%]) had concentrations ≥4 µg/g. 
DISCUSSION
This is the first study to accurately assess fosfomycin penetration into prostatic tissue following oral dosing, with results suggesting that oral fosfomycin achieves sufficient concentrations in most cases to be potentially effective in preventing prostatic infection in patients undergoing TRUS biopsy and to possibly be considered as a therapeutic option for some patients with MDR-GNB prostatitis. Notably, minimum inhibitory concentration (MIC) breakpoints for susceptibility to fosfomycin have only been defined by the Clinical and Laboratory Standards Institute [13] and European Committee on Antimicrobial Susceptibility Testing (EUCAST) [14] for urinary tract infections (≤64 µg/mL and ≤32 µg/mL, respectively). The EUCAST MIC distribution data for fosfomycin suggest that many urinary pathogens have a very low MIC (eg, approximately half of Escherichia coli isolates have an MIC ≤4 µg/mL fosfomycin); however, some strains may be resistant to the drug concentrations achievable in the prostate.
The only previous similar study [10] used a bioassay technique to measure intraprostatic concentrations after a single 4-g intravenous dose of fosfomycin sodium. Mean serum and tissue concentrations were 152.4 ± 29.9 µg/mL and 68.6 ± 28.3 µg/g, respectively-substantially higher than what we identified-but the timing of specimen collection following the intravenous dose (within 1 hour of intravenous administration) was substantially shorter than in our study of oral fosfomycin. Nevertheless, together these studies suggest that fosfomycin does achieve intraprostatic concentrations sufficient to inhibit clinically relevant prostatic pathogens, regardless of whether it is administered intravenously or by the clinically more practical oral route.
Our findings are consistent with the those of the small number of previous studies that have assessed the clinical efficacy of fosfomycin for urological prophylaxis, demonstrating reduced rates of postoperative infection following TURP [15, 16] and TRUS biopsy [17] . Similarly, there is a single published case report of fosfomycin use in the treatment of prostatitis-a case of prostatitis due to vancomycin-resistant Enterococcus, which was successfully treated with 21 days of oral fosfomycin tromethamine given every 3 days [18] .
This study has some limitations. First, all the men in our cohort had benign prostatic hyperplasia of varying severity. Thus, we cannot be sure whether similar drug concentrations would be achieved in patients requiring a TRUS biopsy for suspected malignancy or those suffering from bacterial prostatitis. It is known that prostate blood supply is different in benign prostatic hypertrophy, and this may be a potential explanation for the significantly lower concentrations we found in the peripheral zone samples. It is also possible that drug levels may be higher in the infected prostate due to increased vascularity and increased permeability of vessels in the setting of inflammation. Second, we only examined levels after a single oral fosfomycin dose; thus, we cannot be sure if higher concentrations may be achieved once steady-state has been reached with continuous dosing, whether this is every 2-3 days as is currently recommended for the treatment of complicated urinary tract infection [8] or with more frequent dosing.
Nevertheless, in the current clinical setting of growing concern regarding increasing rates of MDR-GNB infections and fewer and fewer suitable treatment alternatives, we believe our findings are notable because they suggest that oral fosfomycin tromethamine, one of the "forgotten antibiotics" [19] , achieves reasonable levels in the prostate. Thus, for some patients with known or suspected MDR-GNB colonization, it may be considered a potential oral prophylaxis regimen and possibly a treatment option for some cases of bacterial prostatitis. Further clinical and dosing studies are now warranted to evaluate the efficacy of this approach.
